Study of D-verapamil and doxorubicin in cancer treatment
Author Information
Author(s): D. Bissett, D.J. Kerr, J. Cassidy, P. Meredith, U. Traugott, S.B. Kaye
Primary Institution: Beatson Oncology Centre, Western Infirmary, Glasgow
Hypothesis
Can D-verapamil safely enhance the effectiveness of doxorubicin in treating cancer?
Conclusion
D-verapamil at lower doses (800 mg daily) is well tolerated with doxorubicin, while higher doses lead to significant cardiovascular toxicity.
Supporting Evidence
- 5 out of 6 patients experienced hypotension at the highest dose of D-verapamil.
- Patients tolerated 800 mg daily of D-verapamil without significant cardiovascular issues.
- One patient had a partial response to treatment lasting 8 months.
Takeaway
Doctors tested a new drug to help cancer treatment, and found that a lower dose is safer and works better with another medicine.
Methodology
Patients received oral D-verapamil and doxorubicin, with monitoring for toxicity and pharmacokinetics.
Potential Biases
Potential bias in patient selection and reporting of outcomes.
Limitations
The study had a small sample size and was limited to outpatient settings.
Participant Demographics
Median age 49 years, 3 males and 7 females, with various types of cancer.
Statistical Information
P-Value
0.04
Statistical Significance
p=0.04
Want to read the original?
Access the complete publication on the publisher's website